Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 17Completed 16Not yet recruiting 8Active not recruiting 6Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 12Prostatic Neoplasms 7Lung Neoplasms 6Colorectal Neoplasms 5Breast Neoplasms 5Recurrence 4Multiple Myeloma 4Lymphoma, B-Cell 4Lymphoma 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Cancer Pain 3Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Kidney Neoplasms 2

Interventions

semaglutide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Polycystic Ovary Syndrome × 90 days × Clear all
NCT06222437 2026-03-23

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Methodist Health System

Phase 1 Withdrawn

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡